Chandrabali, Bioharmony Therapeutics Inc
Development of Bacteriophage Lysins for Treatment of Infections Caused by Gram-Negative Infections
Novel therapeutic agents called lysins is the solution to the world-wide epidemic of antibiotic resistance. Lysins are a class of enzymes, isolated from bacteriophages that are capable of cleaving bonds in the bacterial cell wall, resulting in the death of the bacteria within seconds after contact. Through evolutionary selection, these lysins target a critical component in the cell wall making resistance to these molecules orders of magnitude less likely than conventional antibiotics. Such properties make lysins uniquely suitable for the treatment of MDR Acinetobacter baumannii (MDR-AB). A majority of AB strains are resistant to at least one classe of antibiotics, one of the deadliest causes of skin infections associated with burns and wounds. Our lead product candidate, BH01, is a fast-acting, biofilm-disrupting topical antimicrobial for the control of MDR-AB. MDR-AB leads WHO's list of 12 "priority" pathogens that pose the greatest threat to human health.